Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: an EAACI position paper published in “Allergy”
DAVOS, Switzerland, October 10, 2023 /PRNewswire/ — Revision of the current nomenclature of allergic diseases, based on symptoms and organ dysfunction, is long overdue in the era of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, facilitating targeted and personalized disease management.
EAACI is the global leader in allergy science and education. The world’s leading thought leaders have come together under the European Academy of Allergy and Clinical Immunology (EAACI) initiative to present a new classification of allergic disorders based on disease mechanisms. Published online today in Allergythe position reveals the new way of perceiving allergic diseases.
We hope that the new classification will profoundly change the approach of health professionals in the management of allergic diseases, because it provides key solutions to a personalized approach.. It focuses on the roles of immunocompetent cells, changes in tissues, the role of microbial infections, and genetic and epigenetic influences, all affecting the protective epithelial barrier of the skin, respiratory tract, and intestine.
The exponential growth of precision diagnostic tools, including omics technology, molecular diagnostics, imaging, sophisticated gene and epigenetic editing, nanotechnology, etc., requires us to introduce a more nuanced concept, evolving the field towards precision and personalized medicine. General consensus and rapid dissemination of the new nomenclature of allergic diseases are essential for the development of the entire field of immune-mediated disease management.
The cultural shift brought by the new nomenclature will lead to new concepts of diagnostic tools, improved therapies and disease management, and guide future research toward more innovative strategies for patient care. This will include new targeted immune therapies, particularly with substances made from living organisms, called biologics, allergen immunotherapy, as well as strategies aimed at changing the composition of the microbiome in humans, among others.
The value of an idea lies in the use made of it. We hope that the new nomenclature of allergic diseases developed by EAACI will help healthcare professionals and patients find a better way to manage and even cure allergic diseases.
Contact:
Professor Marek Jutel MD, Head of the Department of Clinical Immunology, Medical University of Wroclaw, Poland. marek.jutel@all-med.wroclaw.pltelephone +48 71 784 17 40
Teacher. Ioana Agache MD, Faculty of Medicine, Transylvania UniversityBrasov, Romania. ibrumaru@unitbv.rotelephone +40 727 849 321
Teacher. Dr Cezmi A. Akdis, Director of the Swiss Allergy and Asthma Research Institute, Davos, Switzerland. cezmi.akdis@siaf.uzh.chtelephone: ++41 78 738 82 84
Direct link to download the open access article: https://onlinelibrary.wiley.com/doi/10.1111/all.15889
Show original content:https://www.prnewswire.com/apac/news-releases/novel-classification-of-allergic-disorders-published-by-the-european-academy-of-allergy-and-clinical-immunology-siaf-301952132. HTML
SOURCE SIAF
